<b>Conclusions:</b> Leflunomide, Dipyridamole, and Pentoxifylline may serve as promising therapeutic agents for PNH, and the hsa-miR-23a-3p/<i>CXCL8</i> regulatory axis could play a pivotal role in the pathogenesis and progression of PNH. Here, CXCL8 is linked to paroxysmal nocturnal hemoglobinuria.